Corline Biomedical AB (STO:CLBIO)
10.15
+0.10 (1.00%)
Jun 13, 2025, 5:01 PM CET
Corline Biomedical AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 11.74 | 17.67 | 17.01 | 26.21 | 41.64 | 8.99 | Upgrade
|
Cash & Short-Term Investments | 11.74 | 17.67 | 17.01 | 26.21 | 41.64 | 8.99 | Upgrade
|
Cash Growth | -32.84% | 3.86% | -35.09% | -37.05% | 363.07% | -60.66% | Upgrade
|
Accounts Receivable | 1.81 | 1 | 2.93 | 1.66 | 2.3 | 0.91 | Upgrade
|
Other Receivables | 0.95 | 1.63 | 2.29 | 6.82 | 0.47 | 0.45 | Upgrade
|
Receivables | 2.76 | 2.63 | 5.22 | 8.47 | 2.77 | 1.36 | Upgrade
|
Prepaid Expenses | 1.22 | 0.75 | 1.57 | 1.31 | 0.42 | 0.39 | Upgrade
|
Total Current Assets | 15.72 | 21.04 | 23.8 | 36 | 44.82 | 10.74 | Upgrade
|
Property, Plant & Equipment | 0.18 | 0.22 | 0.31 | 0.28 | 0.18 | 0.07 | Upgrade
|
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Long-Term Deferred Charges | 73.67 | 73.5 | 75.99 | 65.5 | 56.66 | 47.47 | Upgrade
|
Total Assets | 89.56 | 94.76 | 100.11 | 101.78 | 101.66 | 58.28 | Upgrade
|
Accounts Payable | 1.8 | 3.09 | 1.97 | 4.34 | 1.96 | 1.44 | Upgrade
|
Accrued Expenses | 2.46 | 2.85 | 3.53 | 2.45 | 4.56 | 2.16 | Upgrade
|
Other Current Liabilities | 1.45 | 1.91 | 1.29 | 0.4 | 2.91 | 2.65 | Upgrade
|
Total Current Liabilities | 5.72 | 7.85 | 6.79 | 7.19 | 9.43 | 6.25 | Upgrade
|
Total Liabilities | 5.72 | 7.85 | 6.79 | 7.19 | 9.43 | 6.25 | Upgrade
|
Common Stock | 3.06 | 3.06 | 2.69 | 2.69 | 2.69 | 2.08 | Upgrade
|
Additional Paid-In Capital | 171.39 | 171.39 | 155.19 | 155.19 | 155.19 | 115.27 | Upgrade
|
Retained Earnings | -90.6 | 37.39 | 61.27 | 54.92 | 36.83 | -65.32 | Upgrade
|
Comprehensive Income & Other | - | -124.92 | -125.83 | -118.21 | -102.47 | - | Upgrade
|
Shareholders' Equity | 83.84 | 86.91 | 93.32 | 94.59 | 92.23 | 52.03 | Upgrade
|
Total Liabilities & Equity | 89.56 | 94.76 | 100.11 | 101.78 | 101.66 | 58.28 | Upgrade
|
Net Cash (Debt) | 11.74 | 17.67 | 17.01 | 26.21 | 41.64 | 8.99 | Upgrade
|
Net Cash Growth | -32.84% | 3.86% | -35.09% | -37.05% | 363.07% | -60.66% | Upgrade
|
Net Cash Per Share | 0.52 | 0.81 | 0.79 | 1.19 | 2.04 | 0.54 | Upgrade
|
Filing Date Shares Outstanding | 24.49 | 24.49 | 21.49 | 21.49 | 21.49 | 18.19 | Upgrade
|
Total Common Shares Outstanding | 24.49 | 24.49 | 21.49 | 21.49 | 21.49 | 16.67 | Upgrade
|
Working Capital | 10 | 13.2 | 17.01 | 28.8 | 35.39 | 4.49 | Upgrade
|
Book Value Per Share | 3.42 | 3.55 | 4.34 | 4.40 | 4.29 | 3.12 | Upgrade
|
Tangible Book Value | 83.84 | 86.91 | 93.32 | 94.59 | 92.23 | 52.03 | Upgrade
|
Tangible Book Value Per Share | 3.42 | 3.55 | 4.34 | 4.40 | 4.29 | 3.12 | Upgrade
|
Machinery | - | 1.27 | 1.27 | 1.14 | 0.99 | 0.85 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.